皮下利妥昔单抗-MiniCHOP联合来那度胺治疗80岁及以上弥漫大B细胞淋巴瘤
这项多中心III期开放随机试验比较R-miniCHOP与R2-miniCHOP在80岁及以上初治DLBCL患者中的疗效。皮下利妥昔单抗在该人群中安全。
要点
- 在80岁及以上DLBCL患者中,R-miniCHOP基础上加用来那度胺未改善总生存。
- R2-miniCHOP组3-4级不良事件发生率为81%,高于R-miniCHOP组的53%。
- 皮下利妥昔单抗用于该老年人群安全性可接受。
核心结论
- 在80岁及以上初治DLBCL患者中,R-miniCHOP联合来那度胺未改善总生存。
- 皮下利妥昔单抗在该老年人群中安全。
研究设计与样本
- 多中心、III期、开放标签、随机试验,比较R-miniCHOP21与R2-miniCHOP21共6周期。
- 共249例80岁及以上初治DLBCL患者随机分配(R-miniCHOP 127例,R2-miniCHOP 122例),按CD10表达和年龄分层。
- 来那度胺剂量为10 mg每日一次,每周期D1-D14;利妥昔单抗首周期IV,第2-6周期皮下注射。
- 主要终点为总生存(OS)。
主要发现
- 中位年龄83岁(范围80-96),55%为非生发中心B细胞(non-GCB)型。
- 在总体人群和非GCB人群中均未观察到OS获益。
- 3-4级不良事件发生率:R-miniCHOP组53%,R2-miniCHOP组81%。
关键数值与推荐
- 3-4级不良事件发生率:R-miniCHOP组53%,R2-miniCHOP组81%。
- 来那度胺剂量:10 mg每日一次,每周期D1-D14。
临床怎么用
- 对于80岁及以上DLBCL患者,R-miniCHOP仍是标准选择之一,加用来那度胺不推荐。
- 皮下利妥昔单抗可用于该老年人群。
- 需关注R2-miniCHOP方案更高的3-4级不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The prognosis of elderly patients with diffuse large B-cell lymphoma (DLBCL) is worse than that of young patients. An attenuated dose of chemotherapy-cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-miniCHOP)-is a good compromise between efficacy and safety in very elderly patients. In combination with R-CHOP (R2-CHOP), lenalidomide has an acceptable level of toxicity and may mitigate the negative prognosis of the non-germinal center B-cell-like phenotype. The Lymphoma Study association conducted a multicentric, phase III, open-label, randomized trial to compare R-miniCHOP and R2-miniCHOP. PATIENTS AND METHODS: Patients of age 80 years or older with untreated DLBCL were randomly assigned into the R-miniCHOP21 group or the R2-miniCHOP21 group for six cycles and stratified according to CD10 expression and age. The first cycle of rituximab was delivered by IV on D1 after a prephase and then delivered subcutaneously on D1 of cycles 2-6. Lenalidomide was delivered at a dose of 10 mg once daily on D1-D14 of each cycle. The primary end point was overall survival (OS). RESULTS: A total of 249 patients with new DLBCL were randomly assigned (127 R-miniCHOP and 122 R2-miniCHOP). The median age was 83 years (range, 80-96), and 55% of the patients were classified as non-GCB. The delivered dose for each R-miniCHOP compound was similar in both arms. Over a median follow-up of 25.1 months, the intention-to-treat analysis revealed that R2-miniCHOP did not improve OS (2-year OS 66% in R-miniCHOP and 65.7% in R2-miniCHOP arm, P = .98) in the overall population or in the non-GCB population. Grade 3-4 adverse events occurred in 53% of patients with R-miniCHOP and in 81% of patients with R2-miniCHOP. CONCLUSION: The addition of lenalidomide to R-miniCHOP does not improve OS. Rituximab delivered subcutaneously was safe in this population.
引用
- Oberic L, Peyrade F, Puyade M, et al. Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. J Clin Oncol. 2021. PMID: 33444079. doi:10.1200/JCO.20.02666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。